Eli Lilly and Company × Gate Bioscience
Eli Lilly entered a collaboration and license agreement with Gate Bioscience to use its 'Molecular Gate' discovery platform. While the specific upfront payment was not disclosed, the agreement included an upfront payment and an equity investment from Lilly. The total potential value of the deal, including development, regulatory, and commercial milestones, is up to $856 million.
The asset
A collaboration and license agreement to use Gate's 'Molecular Gate' drug discovery engine to identify and develop small molecule drugs that eliminate specific, difficult-to-drug proteins.
The record
- Seller status
- Going concern
- Sector
- Biotechnology
- Modalities
- discovery platform, molecular data
- Jurisdiction
- US
What it means if you hold data
This transaction demonstrates a major pharmaceutical company investing in a specialized discovery engine as a core asset, rather than just licensing a specific drug candidate. It underscores the market value of proprietary platforms that can generate novel therapeutics by targeting previously 'undruggable' proteins, a key area of interest for data-driven life sciences.